Lucira Health (Lucira Health) Change In Receivables : $-6.6 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Lucira Health Change In Receivables?

Lucira Health's change in receivables for the quarter that ended in Sep. 2022 was $-3.2 Mil. It means Lucira Health's Accounts Receivable increased by $3.2 Mil from Jun. 2022 to Sep. 2022 .

Lucira Health's change in receivables for the fiscal year that ended in Dec. 2021 was $-34.7 Mil. It means Lucira Health's Accounts Receivable increased by $34.7 Mil from Dec. 2020 to Dec. 2021 .

Lucira Health's Accounts Receivable for the quarter that ended in Sep. 2022 was $14.4 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Lucira Health's Days Sales Outstanding for the three months ended in Sep. 2022 was 38.19.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Lucira Health's liquidation value for the three months ended in Sep. 2022 was $-49.9 Mil.

Lucira Health Change In Receivables Historical Data

The historical data trend for Lucira Health's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucira Health Change In Receivables Chart

Lucira Health Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Change In Receivables

-1.92

0.68

-1.09

-34.70

Lucira Health Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Receivables	Get a 7-Day Free Trial									-8.55	-22.89	-16.09	35.61	-3.23

Lucira Health Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.6 Mil.

Lucira Health (OTCPK:LHDXQ) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Lucira Health's Days Sales Outstanding for the quarter that ended in Sep. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	14.392	/	34.39	*	91
=	38.19

2. In Ben Graham's calculation of liquidation value, Lucira Health's accounts receivable are only considered to be worth 75% of book value:

Lucira Health's liquidation value for the quarter that ended in Sep. 2022 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	39.774	-	128.296	+	0.75 * 14.392	+	0.5 * 55.625
=	-49.9

Lucira Health Change In Receivables Related Terms

Thank you for viewing the detailed overview of Lucira Health's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Lucira Health (Lucira Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucira Health Inc (OTCPK:LHDXQ) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1412 62nd Street, Emeryville, CA, USA, 94608

Website

https://www.lucirahealth.com

Lucira Health Inc is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. It has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fit in the palm of a hand. The company's initial focus is within respiratory diseases, and initially for COVID-19 and influenza Types A and B indications.

Executives

Anthony Joseph Allen	officer: Chief Operations Officer	1412 62ND STREET, EMERYVILLE CA 94608
Epq Llc, Lcovd Safe Ps	other: Less than 10% owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Chad Boeding	other: CEO of 10% owner	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epiq Capital Group, Llc	10 percent owner	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epq Llc, Lcovd Ps	10 percent owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Lflu Ps	other: Less than 10% owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Ltest Ps	other: Less than 10% Owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Richard Clavano Narido	officer: Interim CFO	12 HANSEN CT, MORAGA CA 94556
Ghazi Kashmolah	officer: Ex. VP &Chief Quality Officer	1412 62ND STREET, EMERYVILLE CA 94608
Kevin Walter Collins	officer: Chief Revenue Officer	C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608
Dan George	officer: CFO and Treasurer	1412 62ND STREET, EMERYVILLE CA 94608
Erik T. Engelson	director, officer: President and Chief Executive	1412 62ND STREET, EMERYVILLE CA 94608
Debkishore Mitra	director, officer: Chief Technology Officer	1412 62ND STREET, EMERYVILLE CA 94608
Tamanna Prashar	officer: Vice President	1412 62ND STREET, EMERYVILLE CA 94608
Alison Mccauley	director	C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608